[Report on experiences with ergotropal, with reference to neurocirculatory dysfunction].

E BERGER

Home/Archive/PubMed

PubMed · 13392986

[Report on experiences with ergotropal, with reference to neurocirculatory dysfunction].

E BERGER

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Belladonna Alkaloids Cardiovascular Agents Ergot Alkaloids Neurocirculatory Asthenia BELLADONNA ALKALOIDS/therapeutic use ERGOT ALKALOIDS/therapeutic use NEUROCIRCULATORY ASTHENIA/therapy Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

E BERGER. 1956-10-20. [Report on experiences with ergotropal, with reference to neurocirculatory dysfunction].. https://pubmed.ncbi.nlm.nih.gov/13392986/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Nonestrogen management of menopausal symptoms.

Women who cannot or choose not to take estrogens do have alternatives; however, the options are few and unproven in longterm clinical trials with respect to safety and efficacy. Many available alternative treatments may alleviate the symptoms of the menopause, but do not convey long-term protection against osteoporosis and cardiovascular disease. This article reviews treatment alternatives to estrogen replacement therapy for symptomatic relief.

Belladonna Alkaloids↗

PubMed1990

Psychosis following use of proprietary antidiarrhoeal medicines.

Anticholinergic psychosis was observed to follow ingestion of proprietary antidiarrhoeal preparations by a 63-year-old woman. Possible abuse or accidental overuse of such medicines in the acutely psychotic patient should always be considered.

Belladonna Alkaloids↗

PubMed1987

Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study.

The effect of Bellergal Retard (BR) on climacteric complaints was evaluated versus a placebo in an 8-wk double-blind study, followed by a 4-wk open study in which only BR was used as medication. There was a marked decrease in complaints in both the BR and the placebo groups. Statistically significant differences were observed between the groups after 2 and 4 wk of treatment, indicating superior results with BR. After 8 wk of study however, these differences were no longer apparent. It was concluded that studies on medication for climacteric complaints should not only be placebo-controlled, but also be of at least 8 to 12 wk duration for proper evaluation.

Belladonna Alkaloids↗